Rezolute Inc (OQ:RZLT)

Apr 23, 2024 08:00 am ET
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An...
Mar 06, 2024 07:30 am ET
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results from a preclinical...
Feb 13, 2024 04:05 pm ET
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the...
Jan 24, 2024 08:00 am ET
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team...
Jan 23, 2024 08:00 am ET
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory...
Dec 14, 2023 08:00 am ET
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the initiation of sunRIZE, a pivotal Phase 3 clinical study...
Dec 13, 2023 08:00 am ET
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in...
Nov 24, 2023 11:14 am ET
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index 56% lower than its 5-year high, and 30% of NASDAQ-listed biotech companies trading at negative enterprise value.
Nov 17, 2023 08:00 am ET
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG’s 3rd...
Nov 13, 2023 04:05 pm ET
Rezolute Reports First Quarter Fiscal 2024 Results
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024...
Oct 17, 2023 08:00 am ET
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority...
Oct 11, 2023 08:00 am ET
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of RZ358 to a patient with...
Sep 14, 2023 04:05 pm ET
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results...
Sep 06, 2023 07:00 am ET
Rezolute to Participate in Upcoming Investor Conferences in September
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Nevan...
Jun 27, 2023 04:05 pm ET
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today provided an update on its...
Jun 01, 2023 12:45 pm ET
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME). The report, Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease, highlights the unmet needs and the companies leading innovation in this field. Companies highlighted in the report include Oculis (NASDAQ: OCS) Ocuphire Pharma, OcuTerra, Rezolute (NASDAQ: RZLT) Roche (ROG.SW) and Unity Biotechnology. This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in diabetic eye disease, providing valuable insights for investors and companies.
May 11, 2023 04:05 pm ET
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results...
Mar 23, 2023 04:50 pm ET
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, yesterday hosted a virtual key opinion...
Mar 08, 2023 07:00 am ET
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to transform the treatment paradigms of devastating metabolic diseases, will host a virtual event to...
Feb 10, 2023 04:05 pm ET
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to transform the treatment paradigms of devastating metabolic diseases, today announced its financial...
Dec 15, 2022 07:00 am ET
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that the Company has...
Nov 09, 2022 04:05 pm ET
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results...
Nov 01, 2022 07:00 am ET
Rezolute to Present at the Jefferies London Healthcare Conference
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles...
Oct 20, 2022 07:00 am ET
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced it will present...
Sep 15, 2022 04:05 pm ET
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results...
Sep 07, 2022 07:00 am ET
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced it will present...
Jun 01, 2022 07:00 am ET
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Brian...
May 12, 2022 04:05 pm ET
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced its financial...
May 04, 2022 04:01 pm ET
Rezolute to Host Corporate Update Call on May 4, 2022
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management...
May 04, 2022 09:33 am ET
Rezolute, Inc. Announces Closing of Registered Direct Offering
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of...
May 01, 2022 11:25 pm ET
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the pricing of...
May 01, 2022 02:00 pm ET
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced positive...
Apr 26, 2022 04:05 pm ET
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced a late-breaking...
Mar 29, 2022 07:00 am ET
Rezolute Joins the Rare Disease Company Coalition
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that it has...
Mar 23, 2022 08:30 am ET
Thinking about buying stock in Hycroft Mining, Tilray, 4D pharma, Rezolute, or Creative Realities?
NEW YORK, March 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, TLRY, LBPS, RZLT, and CREX.
Mar 23, 2022 07:00 am ET
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced positive data...
Feb 22, 2022 07:00 am ET
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced topline data from its Phase 1b multiple-ascending dose...
Feb 09, 2022 04:05 pm ET
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the second quarter of fiscal...
Nov 12, 2021 04:05 pm ET
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter of fiscal...
Oct 13, 2021 08:10 am ET
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an...
Oct 12, 2021 04:05 pm ET
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer...
Sep 22, 2021 04:05 pm ET
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today presented results from a natural history study designed to...
Sep 15, 2021 04:56 pm ET
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal...
Sep 09, 2021 04:05 pm ET
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it has begun dosing patients in the second cohort...
Sep 07, 2021 04:05 pm ET
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two...
Aug 10, 2021 07:00 am ET
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has initiated dosing in a Phase 1b...
Aug 03, 2021 07:00 am ET
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two...
Jun 28, 2021 07:00 am ET
Rezolute Added to Russell Microcap® Index
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell Microcap® Index at the conclusion of the 2021...
May 27, 2021 07:00 am ET
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two...
May 20, 2021 07:00 am ET
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD, to its leadership team...
May 18, 2021 07:00 am ET
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose imbalance, today announced the addition of Quan Dong Nguyen, MD, MSc, FAAO, FARVO to its Scientific...
May 17, 2021 04:05 pm ET
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fiscal third quarter ended...
May 17, 2021 07:00 am ET
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit....
May 04, 2021 08:00 am ET
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced positive topline results from its first-in-human Phase 1a clinical study of...
Apr 19, 2021 08:00 am ET
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for rare and metabolic diseases with serious unmet needs, today announced that it has entered into a...
Mar 22, 2021 08:00 am ET
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT) today presented positive results of a Phase 2a study of RZ358 in patients with post-gastric bypass hypoglycemia (PGBH), as well as results of a pharmacologic model of the drug candidate,...
Mar 08, 2021 08:00 am ET
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
Rezolute, Inc. (Nasdaq: RZLT), today announced the appointments of Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA to its Board of Directors. “We are delighted to welcome rare disease experts Dr. Hogenhuis and Dr. Kreher to...
Mar 02, 2021 05:16 pm ET
Rezolute to Participate in Upcoming Investor Conferences in March
Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company’s CEO and Founder, will be presenting at the following upcoming investor conferences:  Cowen 41st Annual Health Care Conference...
Feb 10, 2021 04:05 pm ET
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020. Recent Business Highlights Phase 2b study of RZ358 continues to enroll congenital hyperinsulinism (HI) patients worldwide – The RIZE...
Jan 12, 2021 08:30 am ET
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Rezolute, Inc. (Nasdaq: RZLT), today announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME). The study...
Dec 28, 2020 04:05 pm ET
Rezolute Announces Change of Transfer Agent
Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of IssuerDirect as the Company’s registrar and transfer agent and shareholder support provider....
Dec 03, 2020 08:00 am ET
FDA Clears Rezolute’s IND Application for RZ402
Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for RZ402, an...
Nov 19, 2020 08:00 am ET
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Rezolute, Inc. (Nasdaq:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that Nevan Charles Elam, the Company’s CEO and founder, will be presenting...
Nov 05, 2020 08:00 am ET
Rezolute Announces Uplisting to the Nasdaq Capital Market
Rezolute, Inc. (OCTQB:RZLTD), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that the Company’s common shares have been approved for listing on the...
Oct 09, 2020 08:30 am ET
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
Rezolute, Inc. (OCTQB:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic, and life-threatening diseases, announced today a $41 million private placement which is being led by CAM Capital with...
Sep 10, 2020 08:00 am ET
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), announced today that the Company has appointed veteran global healthcare executive Philippe Fauchet, O.B.E. to its board of directors. Philippe has spent more than 35 years in the...
Jul 27, 2020 08:00 am ET
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in the context of the global COVID-19 pandemic (“Pandemic”), including its Phase 2b study for RZ358 (“RIZE”) in...
Jun 15, 2020 08:30 am ET
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for Research in Vision and Ophthalmology (ARVO) 2020 meeting, titled “Nonclinical safety and pharmacology of RZ402,...
Jun 10, 2020 08:30 am ET
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), today announced that the company has received rare pediatric disease designation (RPD) from the Food and Drug Administration (FDA) for RZ358, a potential treatment for congenital...
Jun 01, 2020 08:30 am ET
Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT) recently announced that it has validated pharmacokinetic (PK) and pharmacodynamic (PD) models of its lead clinical asset, RZ358. Phase 2a data in adult and pediatric patients with congenital...
May 28, 2020 08:30 am ET
Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming oral presentation at this year’s Pediatric Endocrine Society meeting, which will be held virtually. Details of the presentation are as follows:...
May 14, 2020 04:15 pm ET
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an update on the potential impact of the global COVID-19 pandemic on the Company’s clinical and business operations. Through the execution of a business continuity plan,...
Feb 10, 2020 08:30 am ET
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). The Company has...
Jan 27, 2020 08:30 am ET
Rezolute to Present at BIO CEO & Investor Conference 2020
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical development in rare disease at the BIO CEO & Investor Conference 2020, to be held in New York, NY on February 10 –...
Dec 18, 2019 03:00 pm ET
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and type 2 diabetes. AB101 was administered...
Dec 02, 2019 09:25 am ET
Rezolute Management to Present at 2020 Biotech Showcase Conference
Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase Conference in San Francisco on Monday, January 13, 2020 at 9:00 a.m. PT.  The audio portion of the presentation...
Nov 25, 2019 09:25 am ET
Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to its...
Oct 11, 2019 04:24 pm ET
Rezolute Management to Present at 2019 BIO Investor Forum Conference
Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum Conference in San Francisco on Tuesday, October 22, 2019 at 9:00 a.m. PT.  The audio portion of the...
Aug 05, 2019 09:25 am ET
Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity Growth Conference in Boston on Thursday, August 8, 2019 at 8:30 a.m. ET.  The audio portion of the...
Jul 24, 2019 09:25 am ET
Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine,...
Apr 18, 2019 03:48 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
NEW YORK, April 18, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of the following companies in connection with their corresponding upcoming shareholder meeting:
Jan 07, 2019 08:39 am ET
Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that it has entered into a $25 million...
May 16, 2018 08:00 am ET
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that Keith Vendola, M.D., M.B.A.,...
Apr 09, 2018 08:00 am ET
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
LOUISVILLE, Colo., April 09, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that Christine Ferrara,...
Apr 04, 2018 08:00 am ET
Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
LOUISVILLE, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that Hoyoung Huh,...
Apr 03, 2018 01:26 pm ET
Rezolute, Inc. Announces Close of Convertible Note Financing
LOUISVILLE, Colo., April 03, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that with the...
Dec 26, 2017 11:41 am ET
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that it has...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.